5-溴-1-(三异丙基硅基)-1H-吲哚 | 128564-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-溴-1-(三异丙基硅基)-1H-吲哚
• 英文名称: 5-bromo-1-triisopropylsilyl-1H-indole
• 英文别名: 5-Bromo-1-(triisopropylsilyl)-1H-indole；(5-bromoindol-1-yl)-tri(propan-2-yl)silane
• CAS: 128564-66-9
• 化学式: C₁₇H₂₆BrNSi
• 分子量: 352.39
• InChiKey: SQNJTVRBGMQSBC-UHFFFAOYSA-N

物化性质

• 沸点：
  180 °C
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.43
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

SDS

Name:	5-Bromo-1-(triisopropylsilyl)-1h-indole Material Safety Data Sheet
Synonym:	None Known
CAS:	128564-66-9

Section 1 - Chemical Product MSDS Name:5-Bromo-1-(triisopropylsilyl)-1h-indole Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
128564-66-9	5-Bromo-1-(triisopropylsilyl)-1h-indol	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 128564-66-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: Colourless
Odor: Mild/Faint
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 180 deg C @0.5mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H26BrNSi
Molecular Weight: 352.39

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acid chlorides, reducing agents, strong acids, strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 128564-66-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromo-1-(triisopropylsilyl)-1h-indole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 128564-66-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 128564-66-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 128564-66-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-1-(三异丙基硅基)-1H-吲哚 在 叔丁基锂 作用下， 以 乙醇 、 正己烷 为溶剂， 生成 1H-吲哚-2-羧酰胺
  参考文献：
  名称：

  Antimigraine derivatives of indolylcycloalkanylamines

  摘要：

  一系列新颖的环烷基和环烯基胺的衍生物，具有血管性头痛缓解作用。

  公开号：

  US05468768A1
• 作为产物：
  描述：

  三异丙基氯硅烷 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以96%的产率得到5-溴-1-(三异丙基硅基)-1H-吲哚
  参考文献：
  名称：

  [EN] PPAR ACTIVE COMPOUNDS
  [FR] COMPOSES AYANT UNE ACTIVITE SUR DES PPAR

  摘要：

  描述了对PPARs具有活性的化合物，包括全活性化合物。还描述了开发或识别具有所需选择性配置文件的化合物的方法。

  公开号：

  WO2005009958A1

文献信息

• Substituted indolyl and indazolyl derivatives and uses thereof
  申请人：Lee Eun Kyung

  公开号：US20100016312A1

  公开（公告）日：2010-01-21

  This application discloses compounds of generic Formula I: or pharmaceutically acceptable salts thereof, wherein A, R 1 , R 2 , R 3 , R 4 , Q, X, Y, m, p, and q are defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  该应用程序披露了通用式I的化合物或其药用盐，其中A、R1、R2、R3、R4、Q、X、Y、m、p和q的定义如本文所述，用于治疗与单胺再摄取抑制剂相关的疾病。还提供了药物组合物、使用方法和制备化合物的方法。
• Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of β-amyloid-42 aggregation for the treatment of Alzheimer’s disease
  作者：Nampally Sreenivasachary、Heiko Kroth、Pascal Benderitter、Anne Hamel、Yvan Varisco、David T. Hickman、Wolfgang Froestl、Andrea Pfeifer、Andreas Muhs

  DOI：10.1016/j.bmcl.2017.02.001

  日期：2017.3

  design and synthesis of a novel series of indole and 7-azaindole derivatives containing, nitrile, piperidine and N-methyl-piperidine substituents at the 3-position to prevent the pathological self-assembly of amyloid-β. We have further demonstrated that substitution of the azaindole and indole derivatives at the 3 positions is required to obtain compounds with improved physicochemical properties to allow

  淀粉状蛋白-β肽聚集为细胞毒性寡聚体和原纤维聚集体被认为是阿尔茨海默病的主要病理事件之一。在这里，我们报告设计和合成一系列新的吲哚和7-氮杂吲哚衍生物，它们在3位上含有腈，哌啶和N-甲基-哌啶取代基，以防止淀粉样β的病理自组装。我们进一步证明，为了获得具有改善的理化特性以允许脑渗透的化合物，需要在3个位置取代氮杂吲哚和吲哚衍生物。
• Novel compounds, their use and preparation
  申请人：——

  公开号：US20020165251A1

  公开（公告）日：2002-11-07

  The invention provides 2, 3-, 4- or 5-substituted-N1-(arylsulfonyl)indole and (heteroaryl)indole compounds of the general formula (I): 1 in which Ar, R 2 , R 3 , R 4 and R 5 are as defined in the specification. The compounds bind to the 5-HT 6 receptor and are useful for the treatment and prophylaxis of disorders mediated by the 5-HT 6 receptor, such as obesity and CNS disorders.

  这项发明提供了一般式(I)中的2,3-,4-或5-取代-N1-(芳基磺酰基)吲哚和(杂环基)吲哚化合物： 其中Ar，R2，R3，R4和R5如规范中定义。这些化合物与5-HT6受体结合，并可用于治疗和预防由5-HT6受体介导的疾病，如肥胖和中枢神经系统疾病。
• Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
  申请人：Massachusetts Institute of Technology

  公开号：US09353150B2

  公开（公告）日：2016-05-31

  The present application provides, among other things, a compound of Formula I-a and/or I-b, or a pharmaceutically acceptable salt thereof, wherein the variables are defined in the specification. The compounds of the invention are useful for treating various diseases including cancer.

  本申请提供了一种I-a和/或I-b式化合物，或其药学上可接受的盐，其中变量在说明书中定义。本发明的化合物可用于治疗包括癌症在内的各种疾病。
• Substituted indoles and their use as integrin antagonists
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020169200A1

  公开（公告）日：2002-11-14

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (&agr;v) integrins, for example &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , D, X, W, a, m, n, i, j, k and v are defined herein.

  本发明涉及新型取代吲哚化合物，其为αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，其药学上可接受的盐以及其药物组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理性状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等病症。这些化合物具有以下一般式： 1 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此处定义。